Radioactive drug shows promise for hard-to-treat nerve tumors
NCT ID NCT06398444
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 32 times
Summary
This study tests a radioactive drug called Lutetium-177 oxodotreotide in 74 people with advanced neuroendocrine tumors that cannot be removed by surgery and have gotten worse. The drug targets tumor cells to control the disease. The main goals are to check safety and see how many patients' tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NEUROENDOCRINE NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.